AustraliaHealth

Clinuvel (ASX:CUV) secured regulatory approval from Health Canada to market its 16mg SCENESSE drug for adult patients with erythropoietic protoporphyria.

Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million following increased sales of its approved cellular medicine.

Sigma Healthcare (ASX:SIG) announced that co-founders Sam and Jack Gance may sell up to 20% of their combined $7.7 billion stake.

ReNerve (ASX:RNV) has secured a convertible note funding facility of up to $5 million to support its commercialisation strategy.

ResMed (ASX:RMD) signed an agreement to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners.

Imugene (ASX:IMU) secured firm commitments to raise $11.1 million via a share placement to fund its cancer clinical trials.

Argent BioPharma (ASX:RGT) executed a binding transaction framework for the exclusive global licensing of its epilepsy asset CannEpil.

Entropy Neurodynamics (ASX:ENP) reported that all patients in its initial trial cohort achieved a 74% reduction in binge eating episodes.

Osteopore (ASX:OSX) secured market access to Saudi Arabia to commercialise its 3D-printed craniofacial implants in partnership with Zimmer Biomet (NYSE:ZBH).

Clinical-stage company Syntara (ASX:SNT) announced that 20 of 30 patients recorded lower brain inflammation from baseline.

ReNerve (ASX:RNV) obtained marketing approval for its NervAlign Nerve Cuff in Indonesia

OncoSil Medical (ASX:OSL) has completed its Humanitarian Device Exemption application submission to the US FDA.